1-(4-fluorophenyl)-3-methyl-1H-indazole | 1213236-32-8

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 唑类
• 英文名称: 1-(4-fluorophenyl)-3-methyl-1H-indazole
• 英文别名: 1-(4-Fluorophenyl)-3-methylindazole
• CAS: 1213236-32-8
• 化学式: C₁₄H₁₁FN₂
• 分子量: 226.253
• InChiKey: MEOIVAUSLOETPD-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.7
• 重原子数：
  17
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  17.8
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为产物：
  描述：

  (E)-1-(2-(4-fluorophenylamino)phenyl)ethanone oxime 在 2-氨基吡啶 、 甲基磺酰氯 作用下， 以 二氯甲烷 为溶剂， 反应 5.25h， 以87%的产率得到1-(4-fluorophenyl)-3-methyl-1H-indazole
  参考文献：
  名称：

  Synthesis of N-Arylindazoles and Benzimidazoles from a Common Intermediate

  摘要：

  A variety of N-aryl-1H-indazoles and benzimidazoles were synthesized from common arylamino oximes in good to excellent yields The product selectivity depends upon the base used in the reaction, as triethylamine promoted the formation of benzimidazoles, whereas 2-aminopyridine promoted the formation of N-arylindazoles This method is valuable to the synthetic community because both indazoles and benzimidazoles are prevalent in pharmaceuticals

  DOI：

  10.1021/ol101899q

文献信息

• DAST-promoted Beckmann rearrangement/intramolecular cyclization of acyclic ketoximes: access to 2-oxazolines, benzimidazoles and benzoxazoles
  作者：Huiqin Li、Jian Qin、Zonglian Yang、Xiaoxue Guan、Lin Zhang、Peiqiu Liao、Xingqi Li

  DOI：10.1039/c5cc02155c

  日期：——

  The first example of DAST-promoted Beckmann rearrangement/intramolecular cyclization of acyclic ketoximes is described, which affords 2-oxazolines, benzimidazoles and benzoxazoles.

  DAST促进的无环酮肟的贝克曼重排/分子内环化的第一个例子被描述，产生2-噁唑烷，苯并咪唑和苯并噁唑。
• Assembly of <i>N</i>,<i>N</i>-Disubstituted Hydrazines and 1-Aryl-1<i>H</i>-indazoles via Copper-Catalyzed Coupling Reactions
  作者：Xiaodong Xiong、Yongwen Jiang、Dawei Ma

  DOI：10.1021/ol300847v

  日期：2012.5.18

  CuI-catalyzed coupling of N-acyl-N′-substituted hydrazines with aryl iodides takes place at 60–90 °C to afford N-acyl-N′,N′-disubstituted hydrazines regioselectively and thereby gives a facile method for assembling N,N-diaryl hydrazines. N-Acyl-N′-substituted hydrazines can also react with 2-bromoarylcarbonylic compounds at 60–125 °C under the catalysis of CuI/4-hydroxy-l-proline to provide 1-aryl-1H-indazoles

  N-酰基-N'-取代的肼与芳基碘化物的CuI催化偶联在60-90°C下进行，可选择性地提供N-酰基-N '，N'-双取代的肼，从而提供了一种简便的组装N的方法，N-二芳基肼。在CuI / 4-羟基-1-脯氨酸的催化下，N-酰基-N'-取代的肼还可在60-125°C下与2-溴芳基羰基化合物反应，生成1-芳基-1 H-吲唑。
• METHOD OF SYNTHESIZING 1H-INDAZOLE COMPOUNDS
  申请人：Stambuli James P.

  公开号：US20100056800A1

  公开（公告）日：2010-03-04

  A method is provided for synthesizing 1H-indazole compounds in which aromatic carbonyl compounds are reacted with a nitrogen source to form oximes which are then converted to 1H-indazoles.

  提供了一种合成1H-吲唑化合物的方法，其中芳香酮化合物与氮源反应形成肟类，然后转化为1H-吲唑。
• Novel Heterocyclic Substituted Carbonyl Derivatives and Their Use as Dopamine D3 Receptor Ligands
  申请人：Hendrix James A.

  公开号：US20090247509A1

  公开（公告）日：2009-10-01

  The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代羰基衍生物，其表现出对多巴胺D3受体的选择性结合。另一方面，本发明涉及一种治疗与多巴胺D3受体活性相关的中枢神经系统疾病的方法，该方法包括向需要此类治疗的患者施用所述化合物的治疗有效量，以缓解此类疾病。这些化合物可以治疗的中枢神经系统疾病包括精神疾病、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞引起的迟发性运动障碍、吉尔斯-德-拉-图雷综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及制备所述化合物的方法以及将所述化合物作为多巴胺D3受体成像剂的制备和使用方法。
• Novel heterocyclic substituted carbonyl derivatives and their use as dopamine D3 receptor ligands
  申请人：Hendrix A. James

  公开号：US20070161641A1

  公开（公告）日：2007-07-12

  The invention relates to heterocyclic substituted carbonyl derivatives that display selective binding to dopamine D 3 receptors. In another aspect, the invention relates is to a method for treating central nervous system disorders associated with the dopamine D 3 receptor activity in a patient in need of such treatment comprising administering to the subject a therapeutically effective amount of said compounds for alleviation of such disorder. The central nervous system disorders that may be treated with these compounds include Psychotic Disorders, Substance Dependence, Substance Abuse, Dyskinetic Disorders (e.g. Parkinson's Disease, Parkinsonism, Neuroleptic-Induced Tardive Dyskinesia, Gilles de la Tourette Syndrome and Huntington's Disease), Dementia, Anxiety Disorders, Sleep Disorders, Circadian Rhythm Disorders and Mood Disorders. The subject invention is also directed towards processes for the preparation of the compounds described herein as well as methods for making and using the compounds as imaging agents for dopamine D 3 receptors.

  本发明涉及杂环取代羰基衍生物，其具有选择性地与多巴胺D3受体结合。另一方面，本发明涉及一种治疗中枢神经系统疾病的方法，该疾病与多巴胺D3受体活性有关，包括对患者进行治疗，向患者施用所述化合物的治疗有效量，以缓解此类疾病。这些化合物可以治疗的中枢神经系统疾病包括精神病性障碍、物质依赖、物质滥用、运动障碍（例如帕金森病、帕金森综合症、神经阻滞剂引起的迟发性运动障碍、吉尔·德·拉·图雷特综合症和亨廷顿病）、痴呆、焦虑症、睡眠障碍、昼夜节律紊乱和情绪障碍。本发明还涉及所述化合物的制备过程，以及将所述化合物作为多巴胺D3受体成像剂的制备和使用方法。